Cancer, Genomics and Personalised Medicine
The Omics Era

New technologies in genomics, proteomics and metabolomics allows us to get closer to the promise of personalised medicine. This is very crucial in cancer treatment because the reported rate of failure for the initial drug choice is 75% (FDA, 2013).

Current Limitations

Current gene panels being used in personalised medicine test limited sets of genes, do not account for gene-gene interactions or take normal tissue bias into account. Some researchers even argue that DNA tests are only pre-symptomatic and cannot be used in real-time personalisation of medicine.

The Future

RNA can be used to get functional and molecular signatures of cancer from a tumour sample. The measurement of approximately 45,000 data points specific to the patient’s tumor allows for the first time a truly personalized analysis of the molecular aberrations in the cancer tissue.

Personalised Cancer Solutions

Sample-to- Actionable Report

APT’s genomic computational analysis platform, PeCaSo™, powers its tumour-sample-to-physician report service solution for both front-line and non-responding cancer patients through partnering hospitals in India. Bypassing the gene-size and drug-choice limitations of current genetic panels, APT operates on the whole genome to identify networks of genes that can be addressed by currently approved cancer and general drugs.

  • Whole Genome

    25,000 genes

  • Any Cancer, Any Stage

    Solid tumours & Leukemia

  • Multiple chemo & adjuvant options

    Not just cancer-specific chemos but also non-chemo options

  • Adverse Drugs Indicated


PARTNERS & Collaborators

Mazumdar-Shaw Cancer Center, Narayana Hospitals

Health Care Global (HCG)

Comprehensive Blood & Cancer Center (CBCC), CA, USA

and more...


Prahlad Ram
Founder & Chief Scientific Adviser
Prahlad is the founder and chief scientific adviser of APT. He has a BS degree from Rutgers and a Ph.D. from Tulane University. He is an Associate Professor of Systems Biology at the University of Texas, MD Anderson Cancer Center.
Ashwin Nagaraj
Founder & Director
Ashwin has a B.Tech. degree from Indian Institute of Technology, Bombay and a Ph.D. in Biomedical Engineering from State University of New York at Buffalo. He has been involved in the successful transition of concepts/ideas from lab/pre-clinical research to clinical use.
Rajeev Purnaiya
Founder & Director
Rajeev has a B.S. in Industrial & Systems Engineering from the University of Alabama and an M.S. in Industrial Engineering from Texas A&M University. He was the Founder and Managing Director of CyberBazaar, India’s first and largest conferencing company. Post-acquisition of CyberBazaar by WebEx, Inc., he was the Managing Director of WebEx India.